Ethics and ego dissolution: the case of psilocybin.
informed consent
psychiatry
psychopharmacology
psychotherapy
research ethics
Journal
Journal of medical ethics
ISSN: 1473-4257
Titre abrégé: J Med Ethics
Pays: England
ID NLM: 7513619
Informations de publication
Date de publication:
27 May 2020
27 May 2020
Historique:
received:
14
01
2020
revised:
12
03
2020
accepted:
06
04
2020
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
29
5
2020
Statut:
aheadofprint
Résumé
Despite the fact that psychedelics were proscribed from medical research half a century ago, recent, early-phase trials on psychedelics have suggested that they bring novel benefits to patients in the treatment of several mental and substance use disorders. When beneficial, the psychedelic experience is characterized by features unlike those of other psychiatric and medical treatments. These include senses of losing self-importance, ineffable knowledge, feelings of unity and connection with others and encountering 'deep' reality or God. In addition to symptom relief, psychedelic experiences often lead to significant changes in a patient's personality and worldview. Focusing on the case of psilocybin, we argue that the peculiar features of psychedelics pose certain novel risks, which warrant an enhanced informed consent process-one that is more comprehensive than what may be typical for other psychiatric medications. We highlight key issues that should be focused on during the consent process and suggest discussion prompts for enhanced consent in psychedelic psychiatry. Finally, we respond to potential objections before concluding with a discussion of ethical considerations that will arise as psychedelics proceed from highly controlled research environments into mainstream clinical psychiatry.
Identifiants
pubmed: 32461241
pii: medethics-2020-106070
doi: 10.1136/medethics-2020-106070
pmc: PMC9202314
mid: NIHMS1767097
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIMH NIH HHS
ID : R25 MH119043
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Pers. 1992 Jun;60(2):175-215
pubmed: 1635039
Psychiatry Res. 1999 Jun 30;86(3):211-6
pubmed: 10482340
Neurotherapeutics. 2017 Jul;14(3):734-740
pubmed: 28585222
Front Hum Neurosci. 2014 Feb 03;8:20
pubmed: 24550805
Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60
pubmed: 27441452
Clin Pharmacol Ther. 2017 Feb;101(2):209-219
pubmed: 28019026
Psychopharmacology (Berl). 2018 Nov;235(11):3137-3148
pubmed: 30196397
N Engl J Med. 2007 Nov 1;357(18):1834-40
pubmed: 17978292
J Psychopharmacol. 2016 Dec;30(12):1268-1278
pubmed: 27578767
J Psychopharmacol. 2008 Aug;22(6):621-32
pubmed: 18593735
J Psychopharmacol. 2008 Aug;22(6):603-20
pubmed: 18593734
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
J Nerv Ment Dis. 2014 Jul;202(7):513-20
pubmed: 24594678
Psychopharmacology (Berl). 2020 Apr;237(4):1161-1169
pubmed: 31927605
Plast Reconstr Surg. 2013 Dec;132(6):1558-1568
pubmed: 24281583
J Psychopharmacol. 2018 Dec;32(12):1295-1307
pubmed: 30371148
Neuropharmacology. 2018 Nov;142:143-166
pubmed: 29753748
Am J Bioeth. 2016;16(4):60-1
pubmed: 26982929
Front Pharmacol. 2018 Jan 17;8:974
pubmed: 29387009
JAMA. 2011 Mar 16;305(11):1130-1
pubmed: 21406651
Psychol Med. 2020 Sep;50(12):2028-2033
pubmed: 31462346
J Psychopharmacol. 2019 Sep;33(9):1088-1101
pubmed: 31084460
Psychol Bull. 2017 Feb;143(2):117-141
pubmed: 28054797
J Clin Psychopharmacol. 2016 Feb;36(1):77-81
pubmed: 26650973
Lancet Psychiatry. 2018 Jun;5(6):486-497
pubmed: 29728331
J Psychopharmacol. 2017 Jul;31(7):841-850
pubmed: 28095732
Bioethics. 1994 Jul;8(3):191-222
pubmed: 11652346
Acta Psychiatr Scand. 2018 Nov;138(5):368-378
pubmed: 29923178
Psychotherapy (Chic). 2009 Mar;46(1):97-111
pubmed: 22122573
Psychopharmacology (Berl). 2018 Feb;235(2):399-408
pubmed: 29119217
Psychopharmacology (Berl). 2018 Feb;235(2):547-550
pubmed: 28795211
Arch Gen Psychiatry. 1993 Dec;50(12):975-90
pubmed: 8250684
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
Psychopharmacology (Berl). 2016 Mar;233(5):823-9
pubmed: 26612618
N Engl J Med. 2015 Feb 26;372(9):855-62
pubmed: 25714163
PLoS One. 2013 Aug 19;8(8):e63972
pubmed: 23976938
J Law Med Ethics. 2006 Spring;34(1):111-5, 4
pubmed: 16489990
Personal Disord. 2018 Jan;9(1):93-100
pubmed: 28125252
Psychol Med. 2017 Jul;47(9):1668-1677
pubmed: 28166863
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
Neurosci Conscious. 2019 Oct 09;2019(1):niz013
pubmed: 31616570
Sci Rep. 2017 Oct 13;7(1):13187
pubmed: 29030624
J Psychopharmacol. 2011 Nov;25(11):1453-61
pubmed: 21956378
Neuropharmacology. 2018 Nov;142:167-178
pubmed: 29548884
J Affect Disord. 2008 Nov;111(1):67-73
pubmed: 18384882
Am J Psychiatry. 1993 Feb;150(2):188-96
pubmed: 8422069
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43
pubmed: 22308440
Eur Neuropsychopharmacol. 2015 Apr;25(4):483-92
pubmed: 25637267
J Psychopharmacol. 2015 Jan;29(1):57-68
pubmed: 25389218
Am J Psychiatry. 2014 Mar;171(3):262-4
pubmed: 24585328
Ann Transplant. 2005;10(1):9-12
pubmed: 15926744